tacrolimus + cyclosporine A (Astellas Pharma)

This entry refers to the sequential or comparative use of tacrolimus and cyclosporine A, specifically within the context of a clinical trial led by Prof. Dr. Alice Schmidt. The trial (NCT00161109) investigates the conversion of immunosuppressive therapy from tacrolimus to high-dose cyclosporine A in renal transplant recipients who are also positive for the hepatitis C virus (HCV). Both drugs are calcineurin inhibitors used to prevent organ rejection. The rationale for the conversion is based on observations that cyclosporine A may possess anti-HCV activity by interfering with the interaction between the HCV NS5B polymerase and cyclophilin B, potentially reducing viral replication, whereas tacrolimus lacks this effect. The study also monitors the impact on liver function and glucose tolerance, as tacrolimus is frequently associated with a higher risk of post-transplant diabetes mellitus.

Other names

tacrolimus-cyclosporine A conversiontacrolimus + cyclosporine A-Prof. Dr. Alice Schmidt-hepatitis C-kidney transplantation